On July 1, 2021 Hubro Therapeutics, a clinical stage company advancing a pipeline of proprietary peptide cancer vaccines, reported that successful closing of a private placement that will allow the company to initiate clinical development of its lead product candidate FMPV-1 targeting TGFbR2 neo-antigen present in colorectal-, stomach and endometrial-cancer (Press release, Hubro Therapeutics, JUL 1, 2021, View Source [SID1234584938]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hubro Therapeutics announced today that the company has raised 61,5 million NOK (≈6,5 mill.euro) in a heavily oversubscribed financing round backed by existing investors Jandersen Kapital, Investinor, RADFORSK Investeringsstiftelse, Algot Invest and others. The company is grateful for existing shareholders’ continued belief in the company. The company also welcomed new investors, most notably Canica Holding AG who was offered about fifty percent of the newly issued shares.